Avantax Advisory Services Inc. Sells 917 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Avantax Advisory Services Inc. lessened its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 14.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,589 shares of the medical device company’s stock after selling 917 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Tandem Diabetes Care were worth $201,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Brooklyn Investment Group purchased a new position in shares of Tandem Diabetes Care during the third quarter valued at approximately $28,000. AlphaQuest LLC boosted its holdings in Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 541 shares in the last quarter. Jones Financial Companies Lllp increased its position in Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock valued at $41,000 after purchasing an additional 748 shares during the period. McIlrath & Eck LLC bought a new position in Tandem Diabetes Care in the 3rd quarter worth $52,000. Finally, Assetmark Inc. lifted its position in shares of Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock worth $44,000 after purchasing an additional 535 shares during the period.

Insider Buying and Selling

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, March 7th. The stock was bought at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the acquisition, the chief operating officer now owns 10,538 shares of the company’s stock, valued at $190,948.56. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TNDM. Sanford C. Bernstein cut shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $35.00 to $25.00 in a research report on Friday, February 28th. Canaccord Genuity Group reiterated a “buy” rating and set a $63.00 target price on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Citigroup cut Tandem Diabetes Care from a “buy” rating to a “neutral” rating and lowered their target price for the company from $35.00 to $24.00 in a research note on Tuesday, March 4th. Robert W. Baird reduced their price target on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th. Finally, The Goldman Sachs Group lowered their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, Tandem Diabetes Care has a consensus rating of “Moderate Buy” and an average price target of $45.38.

Tandem Diabetes Care Trading Up 0.8 %

Shares of NASDAQ TNDM opened at $19.81 on Friday. The firm’s 50 day moving average price is $28.40 and its 200-day moving average price is $33.25. Tandem Diabetes Care, Inc. has a 52-week low of $17.64 and a 52-week high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company has a market cap of $1.32 billion, a PE ratio of -10.26 and a beta of 1.45.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.